Leading biotechnology company Pluri Inc. (NASDAQ:PLUR) (TASE:PLUR) ("Pluri" or the "Company"), which transforms cells into solutions that promote global wellbeing and sustainability, today announced it has signed a tech transfer and manufacturing agreement with Kadimastem Ltd. (TASE: KDST), a clinical stage biotechnology company developing therapeutic cells for ALS and diabetes treatments. PluriCDMO, launched earlier this year, leverages Pluri's 47,000 square foot good manufacturing practice (GMP) cell production facility to manufacture cell-based products for life science companies.

PluriCDMO will manufacture two cell therapy product candidates for Kadimastem: AstroRx, clinical grade human astrocytes (nervous system supporting cells) for the treatment of ALS for an upcoming U.S. Food and Drug Administration (FDA) Phase 2a study; and IsletRx, clinical grade pancreatic islet cells which produce and secrete insulin and glucagon in response to blood glucose levels, for the treatment of diabetes.

Key to Kadimastem's selection of PluriCDMO is Pluri's unparalleled expertise and experience in developing and manufacturing cell-based products in GMP grade for clinical use. From initial clinical trial batches to mass scale commercial production, PluriCDMO is a long-term partner and service provider for the cell therapy production needs of the most innovative companies.